Connect with us

Media OutReach

VinFuture Prize empowered the woman scientist Dr. Firdausi Qadri to give back to Bangladesh

Published

on

HANOI, VIETNAM – Media OutReach Neswire – 24 March 2025 – A leading force in cholera vaccine research, Dr. Firdausi Qadri at the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) has dedicated her career to combating this dramatic mortal disease through the innovative improvement of oral cholera vaccination, aiming to large-scale vaccination effort in developing countries.

Sharing with the VinFuture Foundation, Dr. Qadri reflects on her groundbreaking work and her passion for expanding STEM education for women. In the face of societal barriers, particularly in Bangladesh, she remains committed to empowering women in science and using her VinFuture Prize value to strengthen the country’s scientific community.

The ongoing battle against cholera

Having established herself as one of the scientific titans in the vaccine area, Dr. Qadri has developed a single oral dose of an affordable cholera vaccine to address the public health needs in Bangladesh. Her research opens the possibility of large-scale vaccination campaigns in poor countries to prevent outbreaks and reduce the healthcare cost burden, allowing them to invest in education and economic activities. This revolutionizing discovery has earned her global recognition, including the 2024 VinFuture Special Prize for Innovators from Developing Countries.

The VinFuture Prize was completely unexpected, but it has given me immense energy and a profound sense of purpose to turn scientific solutions into real-world applications that benefit those in adverse settings, including humanitarian crises globally,” Dr. Qadri said.

Beyond its personal significance, the VinFuture Prize also empowered Dr. Qadri to give back to her home country. In 2014, Dr. Qadri formed a non-profit research institution called the ideSHi (Institute for Developing Science and Health Initiatives) located on the 11th floor of Blue Moon Gram Tower in ECB Chattar, Dhaka. She shared an astounding initiative to expand this institute using the 500,000 USD prize value from VinFuture, “Together with the VinFuture Prize money and a quarter of my personal funds, I took a bold step forward, acquiring an additional 5,000 square feet of space within the same building as ideSHi’s original facility,” she elaborated.

This facility is a bold initiative dedicated to improving public health and nurturing the next generation of scientists. Since then, this institute provides state-of-the-art facilities, offers training programs, collaborates with international partners, conducts research on genetic diseases including thalassemia – the most common blood disorder in Bangladesh – as well as infectious diseases.

Over the past decade, ideSHi has expanded tremendously, and this new extension will allow us to tackle even more critical health challenges while further strengthening scientific capacity in Bangladesh,” she shared. “With prize money received from VinFuture, I am confident that this support will help ideSHi develop pragmatic solutions to public health challenges and ultimately help advance Bangladesh’s position in biomedical research.”

The achievement results in her determination after witnessing firsthand the dire impact of cholera and diarrheal diseases. Her journey began as a scientist with a deep passion for immunology, later on extended her work beyond the laboratory to the field, fully devoted to the cause of uplifting the lives of Bangladesh and beyond.

However, through her extensive work in diarrheal diseases at their main hospital in Bangladesh, Dr. Qadri estimates an annual intake of approximately 200,000 patients, with 90-95% comes from impoverished backgrounds. Living in overcrowded conditions with shared toilets, kitchens, and bathrooms, they face rapid disease transmission. “If one person contracts cholera, the infection can spread to three other people in the family and beyond due to contaminated hands and food,” Dr. Qadri explained. “It’s very difficult to control.”

Recognizing the persistent devastation of global health crises, Dr. Qadri extended her research beyond the laboratory. She conducted field studies on vaccine effectiveness, distribution strategies, and public health interventions. Her efforts extended beyond academia as she worked more with the government, advocating for necessary actions to improve healthcare access.

Over 15 to 20 years, my work has evolved to encompass not just vaccine development, but also implementation strategies – exploring the effectiveness of different modes in delivering vaccines and understanding how to integrate water, sanitation, and hygiene (WASH) with vaccination programs to achieve cholera control,” she noted.

Dr. Qadri emphasized that cholera remains a disease of poverty, often overlooked due to its association with inadequate sanitation and clean water access. She also pointed out that some governments were reluctant to acknowledge the disease’s prevalence, fearing for their global image. Therefore, she expressed deep gratitude and immense joy at being recognized by such a prestigious global award as the VinFuture Prize. “This recognition is a tremendous honor and serves as a motivation for me to move ahead,” she shared.

Breaking glass ceilings

Dr. Qadri’s dedication to rigorous scientific research and her success in the cholera vaccine area serves as an inspiration for young women all over the world. However, ​​for women in science, particularly in developing countries across Asia, the road is often fraught with challenges. Deep-seated prejudices and invisible glass ceilings make it difficult for women to gain recognition in male-dominated fields.

I always want to be known as a scientist, not a “woman scientist,” who works alongside men as equals“, Dr. Qadri shared. “But I cannot deny that acceptance has not always come easily.”

The unwavering support of her family played a crucial role, encouraging her to push boundaries and proving that a woman is just as capable as a man. “I traveled to remote areas, worked long hours in the field, and committed myself fully to scientific research. I have managed to overcome many prejudices, though challenges remain,” she noted.

It is also a driving force that motivates her to passionately advocate for empowering women in STEM education. According to her, science, technology, engineering, and mathematics are the foundation of progress, driving innovation and shaping the future. Yet, women remain underrepresented in STEM fields, not only in developing countries but even in advanced economies.

If we truly want to make a meaningful contribution to the world, women must be part of this transformation,” Dr. Qadri emphasized.

Many hesitate to pursue careers in STEM, not due to a lack of ability but because of societal expectations and deeply ingrained biases. Fields including engineering and mathematics, in particular, remain male-dominated, with cultural norms dictating which professions are deemed “suitable” for women.

Another critical factor is the cost and commitment required. STEM education is more demanding, expensive, and time-intensive compared to fields including finance or commerce. Success in STEM requires years of dedication and persistence, making it an uphill battle, especially for women who must balance professional ambitions with societal expectations of family life.

I try to use my journey to show young women that it is possible to have a family, raise children, and do science.” She remarked, “You just need to know the mechanism to do it. There is no secret formula: just focus, perseverance, and unwavering commitment to the work you choose to do.”

Addressing health disparities

Driven by the goal to seek effective preventive public health solutions for Bangladesh and other developing countries, Dr. Qadri focuses on large-scale clinical studies using Vietnamese live vaccine train, which allowed her to conclude the benefit, power and feasibility of an oral dose of an affordable vaccine.

Vietnam, which has been able to control cholera better through concerted public health efforts, has always been an example I reflected on.” She stated, “If Vietnam can better control cholera through a comprehensive public health approach, why can’t we?”

Besides vaccination, the scientific titan emphasized the need for a holistic approach, including improvements in WASH education, and surveillance. However, behavioral change and access to clean water remain significant hurdles. Thus, according to Dr. Qadri, to provide crucial protection in the short term, there are two key strategies: reactive vaccination during an outbreak and preventive vaccination to build immunity.

However, a major obstacle the world faces is the global shortage of cholera vaccines. “Despite cholera affecting millions across Asia, Africa, and Latin America, only 80 million vaccine doses are currently available annually. This is far below what is needed – Bangladesh alone requires 100 million doses in the coming years,” she noted.

The economic constraints surrounding cholera vaccines also present a challenge. Since cholera is often considered a “disease of poverty,” many pharmaceutical companies hesitate to invest in its production due to low profit margins. “This is already happening,” she stressed.

To address this, Dr. Qadri actively advocates for increased vaccine production in Bangladesh. She shared that one of her team’s key achievements has been demonstrating that in a major outbreak, giving the vaccine in a reactive way can quickly reduce the number of cases. “We have implemented this strategy in multiple regions of Bangladesh,” Dr. Qadri added.

More importantly, as a result of our dedication, we now have a national cholera control plan, centered on preventive vaccination, ensuring that people receive doses regularly – whether annually or every three years – to stay protected before outbreaks occur. This is a significant milestone in our fight against the disease.” she said.
Hashtag: #VinFuture

The issuer is solely responsible for the content of this announcement.

VinFuture

The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation’s core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide.

The nomination period for the 2025 VinFuture Prize will close at 2:00 PM on April 17, 2025 (Vietnam time, GMT+7).

The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring women innovators, innovators from developing countries, and innovators with outstanding achievements in emerging fields.

Advertisement

Media OutReach

Asia Coach Group Partners with Veteran Business Consultant Rick Tam to Launch “Business Breakthrough” Programme for Hong Kong SMEs

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – Asia Coach Group Limited announced today its partnership with seasoned business consultant Rick Tam to launch the “Business Breakthrough” enterprise training programme, designed to help Hong Kong SME owners strengthen their business models, improve cash flow, and enhance financing capabilities.

Rick Tam, Founder of “Business Breakthrough” Coaching Programme for Hong Kong SMEs

Challenging Business Environment Demands New Solutions

Hong Kong’s SMEs are facing unprecedented operational pressures. According to a survey by CPA Australia, 37% of small businesses in Hong Kong struggle to obtain external financing. Data from Airwallex further reveals that 96% of SMEs have experienced cash flow difficulties in the past year. With property asset values declining, banks’ insistence on property collateral for loans has left many enterprises in financial distress.

Responding to Market Needs with Systematic Business Upgrade Solutions

“Hong Kong has never lacked capital—what’s missing is the mechanism to connect businesses with it,” Rick Tam noted. The programme addresses common pain points faced by local SMEs, including declining profits, low business valuations, tight cash flow, and recruitment challenges. Built upon the four-pillar framework of “Commerce, Strategy, Breakthrough, and Structure,” the curriculum covers stabilising cash flow and enhancing financial flexibility, repositioning businesses and improving client quality, reshaping product value and expanding profit margins, as well as systematising operations and attracting investors. The programme commits to helping participants improve cash flow, increase business value, and strengthen their business models within 90 days.

Four Practical Tools for Immediate Application

Participants will acquire four core tools: the “Cash Flow Vortex System” for rapid assessment of financial status and establishing safety buffers; the “A.T.C. Client Leverage Ladder” for repositioning and enhancing client value; the “High-Value Breakthrough Method” for creating products with greater value and trust; and the “Marketing Triangle Matrix” for integrating human resources, client bases, and operational systems to plan business expansion. The programme adopts a six-step progressive model—from restructuring business models, improving profit margins, attracting capital injection, building high-performance teams, and systematising operations, to ultimately helping business owners reclaim their time and freedom.

Instructor Credentials

Programme instructor Rick Tam is a graduate of the University of Hong Kong’s Business School and currently serves as CEO of two family offices and chief consultant to several others. He holds the CFPCM Certified Financial Planner designation. Tam has founded more than nine brands spanning wealth management, securities, and food and beverage sectors, and has guided over 1,000 participants through business expansion.

As Hong Kong’s economy seeks transformation, channelling capital precisely into the real economy through the “Business Breakthrough” approach offers more than a lifeline for SMEs—it injects vital momentum into Hong Kong’s long-term economic development.

Hashtag: #RickTam #AsiaCoach

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer

Published

on

SINGAPORE – Media OutReach Newswire – 9 February 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.

The acquisition of the brands supports Zuellig Pharma’s strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.

“This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk® and Vapex® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands’ legacy with Zuellig Pharma’s regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers.” said John Graham, CEO of Zuellig Pharma.

Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

International Entertainment Corporation to Hold EGM on 26 February 2026 for Proposed Convertible Notes Issuance

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – International Entertainment Corporation (the “Company“, together with its subsidiaries, the “Group“; HKEX stock code: 1009) will hold an extraordinary general meeting (the “EGM”) on 26 February 2026 at 11:00 a.m. for shareholders to vote on resolutions related to the proposed issuance of up to HK$1.6 billion convertible notes (the “Notes“) to DigiPlus Interactive Corp. (the “Subscriber“) (Philippine Stock Exchange stock symbol: PLUS).

DigiPlus Interactive Corp., named as one of the Fortune Southeast Asia 500, together with its subsidiaries, is an innovative digital entertainment group in the Philippines and is a leader in the casinos and gaming industry. On 17 November 2025, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company conditionally agreed to issue and the Subscriber conditionally agreed to subscribe for the Notes in two tranches with a maturity of five years and an interest rate of 3% per annum.

Upon full conversion of the Notes at the initial Conversion Price, a total of 1,600,000,000 Shares will be issued by the Company, representing approximately 53.89% of the issued share capital of the Company as enlarged by the issue and allotment of the Conversion Shares. As such, the Subscriber will be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code, unless the Whitewash Waiver is granted and approved.

The initial Conversion Price of HK$1.00 per Conversion Share represents a discount of approximately 3.85% to the closing price of HK$1.04 per Share as quoted on the Stock Exchange on the Latest Practicable Date (6 February 2026).

The board of Directors (the “Board“) believes that the Subscription would be beneficial to improving and strengthening the Group’s liquidity and financial position on a longer-term basis. In the event that the Subscriber converts part or the full amount of the Notes into the Conversion Shares, it will also broaden the shareholder and capital base of the Company. The Group intends to apply part of the net proceeds raised from the issuance of the Notes of approximately HK$489.22 million for the early repayment of the Promissory Notes and interest accrued thereon (the “PN Repayment“), and approximately HK$392.39 million to early repay the Secured Bank Borrowing to achieve immediate interest savings.

The remaining net proceeds will primarily be used for funding the Investment Commitment and attractive investment/business opportunity(ies); and as general working capital of the Group. The Investment Commitment is currently expected to include capital investments for acquisition of land for the expansion of the Group’s integrated resort in Manila City in the Philippines (the ”Hotel”) and the construction of additional hotel rooms, for provision of other amenities of the integrated resort, and for ongoing upgrades, refurbishments and renovations to the facilities and infrastructures of both the Hotel and the Group’s existing casino (the “Casino“).

The Independent Board Committee, which comprises all the independent non-executive Directors, is of the opinion that (i) the terms of the Subscription Agreement are on normal commercial terms, and the terms of the Subscription, the Whitewash Waiver and the Special Deal (the PN Repayment to the PN Holder) are fair and reasonable so far as the Independent Shareholders are concerned; and (ii) the Subscription, the Whitewash Waiver and the Special Deal are in the interests of the Company and the Shareholders as a whole and as far as the Independent Shareholders are concerned. It, therefore, recommends the Independent Shareholders to vote in favour of the relevant resolution(s) to be proposed at the EGM.

Hashtag: #InternationalEntertainmentCorporation

The issuer is solely responsible for the content of this announcement.

About International Entertainment Corporation (HKEX: 1009)

International Entertainment Corporation is an investment holding company. The Company and its subsidiaries are principally involved in hotel operations, operating the gaming business under provisional licence and leasing of gaming venues at the hotel complex of the Group in Metro Manila in the Republic of the Philippines to a tenant for authorized gaming operation and live poker events in Macau.

Continue Reading

Trending